Dengue fever in the immunocompromised: a retrospective cohort study on Reunion Island
This retrospective cohort study on Reunion Island reveals that immunocompromised patients, particularly those with solid neoplasms, face a significantly higher risk of severe dengue fever compared to non-immunocompromised individuals, highlighting the need for heightened clinical vigilance in this older, more comorbid population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Mosquitoes are more than just a summer nuisance; in many parts of the world, they are vectors for viruses that can make people very sick. One of the most widespread of these is dengue fever, a disease transmitted by specific types of mosquitoes that thrive in tropical and subtropical climates. For most people, a dengue infection feels like a severe flu, with high fever, intense body aches, and pain behind the eyes. However, for a small number of patients, the illness can escalate into a dangerous condition where the body's blood vessels leak, organs begin to fail, or severe bleeding occurs. While doctors know that certain pre-existing health conditions, like heart disease or diabetes, can make dengue worse, there has been a significant gap in understanding how the virus affects people whose immune systems are already weakened. These are patients whose bodies are already fighting other battles, such as cancer, organ transplants, or autoimmune diseases, often requiring medications that suppress the immune system to keep those conditions in check. When such a person catches dengue, it is unclear whether their weakened defenses make the virus more deadly, or if the lack of an immune response actually protects them from the severe inflammation that often causes the worst damage.
To answer this question, a team of researchers on Reunion Island, a French territory in the Indian Ocean that frequently faces dengue outbreaks, conducted a detailed look back at patient records from 2019. They focused on a specific group of 847 people who were admitted to the university hospital with a confirmed diagnosis of dengue, verified by a laboratory test that detects the virus's genetic material. Among these patients, the researchers identified 41 individuals who were immunocompromised, meaning they had conditions or were taking treatments that lowered their immune defenses. These conditions included various forms of cancer, organ transplants, liver cirrhosis, and autoimmune diseases treated with strong medications. The team compared these 41 patients against the remaining 806 patients who had healthy immune systems, carefully examining their ages, medical histories, symptoms, and how their bodies reacted to the infection.
The researchers found that the immunocompromised group was significantly older and carried a heavier burden of other chronic illnesses compared to the general dengue patients. When these patients arrived at the hospital, they were more likely to have persistent vomiting and diarrhea. As the infection progressed, the data revealed a stark difference in outcomes: the immunocompromised patients were far more likely to be hospitalized, to develop complications, and to meet the criteria for severe dengue. In fact, nearly 40 percent of the immunocompromised patients developed severe dengue, compared to only 19 percent of those with healthy immune systems. The most common reason for this severity was acute kidney failure, where the kidneys stop working properly, a condition that occurred much more frequently in the weakened group. Despite these higher rates of severe illness and organ failure, the study noted that the patients in this group did not necessarily show more of the standard "warning signs" that doctors usually look for to predict a severe case, suggesting that the usual rules for spotting danger might not apply to them.
When the researchers broke down the immunocompromised group further, a specific pattern emerged. The increased risk of severe disease was driven almost entirely by patients with solid tumors, such as cancers of the prostate, breast, or lung. These patients were the oldest in the study and had the most other health problems. In contrast, patients with other types of immune suppression, such as those who had received kidney transplants or those with autoimmune diseases, did not show the same elevated risk of severe dengue. In fact, the transplant recipients fared quite well, with none of the two patients in that specific subgroup developing severe dengue. This finding challenges the idea that a suppressed immune system always leads to worse outcomes; instead, it suggests that the specific cause of the immune suppression matters greatly. The researchers also observed that for the transplant patients, stopping their anti-rejection medications did not seem necessary, as their outcomes were reassuring, whereas for the cancer patients, the combination of their age, other illnesses, and the cancer itself created a perfect storm for severe disease.
The study concludes that while dengue fever is a threat to everyone, it poses a particularly high and unpredictable risk to older patients with solid cancers. These individuals are more likely to suffer from organ failure, specifically kidney damage, even if they do not display the classic warning signs that usually alert doctors to a worsening condition. The findings serve as a crucial guide for clinicians, suggesting that they should maintain a high level of vigilance when treating immunocompromised patients, particularly those with cancer, as their bodies may not signal trouble in the expected ways. For other groups, such as organ transplant recipients, the data offers a measure of reassurance, indicating that their immune suppression might not increase their risk of the most dangerous forms of the disease. Ultimately, this research highlights that not all weakened immune systems react to dengue in the same way, and understanding these differences is essential for providing the right care to the most vulnerable patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.